RNA virus

DGAP-News: Publication in PNAS unveils molecular pathway required for influenza virus replication with large potential as an antiviral drug target

Tuesday, June 30, 2020 - 2:10pm

[1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.

Key Points: 
  • [1] , [2] The research identifies and confirms the full molecular chain of events connecting the virus-activated Raf/MEK/ERK signalling pathway via its downstream target RSK to the final export of vRNPs during an influenza virus infection.
  • As the virus is unable to perform this function by itself, this represents an Achilles heel of virus replication.
  • [3]
    "By targeting the enzyme MEK, an essential component of the signalling cascade, ATR-002 inhibits this pathway and, thus, leads to a blockade of viral replication.
  • This pathway is central for replication of many RNA viruses, such as the influenza virus, hantavirus or respiratory syncytial virus (RSV) and also SARS-CoV-2, the virus that causes COVID-19.

Novomer to Probe Functional Beta-Lactones to Enhance Virus Deactivation

Wednesday, June 17, 2020 - 10:05pm

New functional beta-lactone architectures may have improved performance relative to beta-propiolactone owing to differences in lipophilicity and reactivity with functional groups commonly found in viruses.

Key Points: 
  • New functional beta-lactone architectures may have improved performance relative to beta-propiolactone owing to differences in lipophilicity and reactivity with functional groups commonly found in viruses.
  • Novel functionalized beta-propiolactones may unlock the key to selectively targeting the virus RNA for successful inactivation.
  • By utilizing Novomers catalyst and process technology, these novel materials can be produced in high volumes and high quality required for this important application, says Geoff Coates, Novomer Co-Founder.
  • Novomer, Inc. is a leading developer of chemical conversion technology to address market needs for transformable, functional, and high carbon utility materials.

Electromedical Technologies, Inc. Announces Research Collaboration with Nazarbayev University to Study Effects of Electrical Frequencies on Cell Signaling and Virus Replication

Thursday, April 23, 2020 - 11:00am

There is also an interest to expand the electro-modulation studies to identify most effective frequencies interfering with replication and assembly of large single-stranded RNA viruses.

Key Points: 
  • There is also an interest to expand the electro-modulation studies to identify most effective frequencies interfering with replication and assembly of large single-stranded RNA viruses.
  • Commenting further, Mr. Wolfson said, More research is needed right away on this very important topic, especially now.
  • Commenting further, Dr. Sarbassov said, However, given todays worldwide crisis, it will be important to explore these effects on coronavirus replication.
  • Please visit Nazarbayev University website https://research.nu.edu.kz/en/ to find comprehensive information on the NU research activities and profiles of faculty and researchers.

 Emergex Signs Agreement with GEORGE MASON UNIVERSITY for Highly Pathogenic RNA Virus Studies

Wednesday, April 22, 2020 - 12:02pm
Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20200422005428/en/
    The agreement specifies that George Mason Universitys National Center for Biodefense and Infectious Diseases will provide their unique expertise and resources as a partner in the development of Emergexs vaccines against highly pathogenic RNA viruses.
  • Professor Thomas Rademacher, CEO and co-founder of Emergex, commented, Everyone in the world today has or will be affected by highly pathogenic RNA viruses such as bird flu, Ebola, COVID-19, etc.
  • We are therefore very excited to announce today this agreement with George Mason University, which adds an important capability to Emergexs vaccine program.
  • The Institute for Biohealth Innovation (IBI) promotes and supports biohealth-related research activities of faculty, staff, and students at George Mason University.

Leader in Global Health and Emerging Pathogens at Mount Sinai Elected to the National Academy of Sciences

Wednesday, May 8, 2019 - 6:00pm

For more than 20 years, Dr. Garca-Sastre has researched the molecular biology of influenza viruses and several other negative-strand RNA viruses.

Key Points: 
  • For more than 20 years, Dr. Garca-Sastre has researched the molecular biology of influenza viruses and several other negative-strand RNA viruses.
  • The New York Eye and Ear Infirmary of Mount Sinai is ranked 11th nationally for Ophthalmology and 44th for Ear, Nose, and Throat.
  • Mount Sinai Beth Israel, Mount Sinai St. Luke's, Mount Sinai West, and South Nassau Communities Hospital are ranked regionally.
  • For more information, visit http://www.mountsinai.org/ , or find Mount Sinai on Facebook, Twitter, Instagram, and YouTube.